Literature DB >> 34811598

Liver enzymes and risk of ocular motor cranial nerve palsy: a nationwide population-based study.

Joonhyoung Kim1, Kyungdo Han2, Juhwan Yoo3, Kyung-Ah Park4, Sei Yeul Oh5.   

Abstract

This study aimed to assess the associations between liver enzymes including γ-glutamyl transferase (GGT) and the development of ocular motor cranial nerve palsy (CNP) using the National Sample Cohort database from Korea's National Health Insurance Service. We analyzed data from 4,233,273 medical screening examinees aged 20 years or more in 2009. Study participants were followed up until December 31, 2018. A Cox proportional hazard regression analysis was performed for quartiles of liver enzymes to determine the linkage between each value and ocular motor CNP using quartile 1 as a reference after adjusting for potential confounders. A total of 5,807 (0.14%) patients developed ocular motor CNP during the follow-up period of 8.22 ± 0.94 years. The incidence of ocular motor CNP gradually increased as the GGT levels increased. The highest quartile of the GGT group had hazard ratio (HR) of 1.245 (95% confidence interval [CI], 1.136-1.365). Regarding alanine aminotransferase (ALT), the highest quartile of the ALT group had HR of 1.141 (95% CI, 1.049-1.241). However, the incidence of ocular motor CNP did not gradually increase as the ALT levels increased. The coexistence of the increased level of GGT, metabolic syndrome, and obesity showed a stronger association with ocular motor CNP development (HR, 1.331; 95% CI, 1.173, 1.511) compared to having a single factor or two factors. In conclusion, our population-based cohort study demonstrated a significant association between serum GGT level and the incidence of ocular motor CNP, suggesting that GGT could be a new clinical marker for predicting the occurrence of ocular motor CNP.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Fourth cranial nerve palsy; Liver enzymes; Ocular motor cranial nerve palsy; Sixth cranial nerve palsy; Third cranial nerve palsy; γ-Glutamyl transferase

Mesh:

Substances:

Year:  2021        PMID: 34811598     DOI: 10.1007/s10072-021-05735-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  55 in total

1.  Serum gamma-glutamyltransferase as a risk factor of ischemic stroke might be independent of alcohol consumption.

Authors:  Michele Emdin; Claudio Passino; Luigi Donato; Aldo Paolicchi; Alfonso Pompella
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

Review 2.  Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque.

Authors:  Michele Emdin; Alfonso Pompella; Aldo Paolicchi
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

Review 3.  Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis.

Authors:  Abigail Fraser; Ross Harris; Naveed Sattar; Shah Ebrahim; George Davey Smith; D A Lawlor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-11       Impact factor: 8.311

4.  Plasma gamma-glutamyltransferase, cysteinyl-glycine, and oxidized low-density lipoprotein: a pathway associated with myocardial infarction risk?

Authors:  Dagmar Drogan; Cornelia Weikert; Jutta Dierkes; Kerstin Klipstein-Grobusch; Brian Buijsse; Matthias Möhlig; Andreas F H Pfeiffer; Tobias Pischon; Joachim Spranger; Heiner Boeing
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07-29       Impact factor: 8.311

Review 5.  Association between Gamma-Glutamyltransferase Level and Risk of Stroke: A Systematic Review and Meta-analysis of Prospective Studies.

Authors:  Xiao-Wei Zhang; Min Li; Wen-Shang Hou; Kun Li; Jing-Ran Zhou; Zhen-Yu Tang
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-12       Impact factor: 2.136

6.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

7.  Serum -glytamyl transpeptidase activity in liver disease.

Authors:  J B Whitfield; R E Pounder; G Neale; D W Moss
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

8.  Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes?

Authors:  D-H Lee; M W Steffes; D R Jacobs
Journal:  Diabetologia       Date:  2007-12-11       Impact factor: 10.122

9.  Association between serum gamma-glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey.

Authors:  Duk-Hee Lee; Brian Buijsse; Lyn Steffen; Jordan Holtzman; Russell Luepker; David R Jacobs
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-02

10.  Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.

Authors:  C Grimm; G Hofstetter; S Aust; I Mutz-Dehbalaie; M Bruch; G Heinze; J Rahhal-Schupp; A Reinthaller; N Concin; S Polterauer
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.